+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2019

  • ID: 4866594
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 272 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AlloVir Inc
  • Bristol-Myers Squibb Co
  • Galenbio Ltd
  • Immunotech Biopharm Ltd
  • Ono Pharmaceutical Co Ltd
  • Savoy Pharmaceuticals Inc
  • MORE
Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2019, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 4, 10, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 3, 6 and 4 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AlloVir Inc
  • Bristol-Myers Squibb Co
  • Galenbio Ltd
  • Immunotech Biopharm Ltd
  • Ono Pharmaceutical Co Ltd
  • Savoy Pharmaceuticals Inc
  • MORE
Introduction
Epstein-Barr Virus (HHV-4) Infections - Overview
Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development
Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment
Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development
Epstein-Barr Virus (HHV-4) Infections - Drug Profiles
Epstein-Barr Virus (HHV-4) Infections - Dormant Projects
Epstein-Barr Virus (HHV-4) Infections - Discontinued Products
Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Companies, H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 9: Products under Development by Universities/Institutes, H2 2019
Table 10: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 11: Number of Products by Stage and Target, H2 2019
Table 12: Number of Products by Stage and Mechanism of Action, H2 2019
Table 13: Number of Products by Stage and Route of Administration, H2 2019
Table 14: Number of Products by Stage and Molecule Type, H2 2019
Table 15: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2019
Table 16: Epstein-Barr Virus (HHV-4) Infections - Pipeline by AlloVir Inc, H2 2019
Table 17: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2019
Table 18: Epstein-Barr Virus (HHV-4) Infections - Pipeline by bluebird bio Inc, H2 2019
Table 19: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Boryung ViGenCell Inc, H2 2019
Table 20: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 21: Epstein-Barr Virus (HHV-4) Infections - Pipeline by China Immunotech Co Ltd, H2 2019
Table 22: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cullinan Oncology LLC, H2 2019
Table 23: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Eutilex Co Ltd, H2 2019
Table 24: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Galenbio Ltd, H2 2019
Table 25: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Geneius Biotechnology Inc, H2 2019
Table 26: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Genocea Biosciences Inc, H2 2019
Table 27: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Good T Cells Inc, H2 2019
Table 28: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Immunotech Biopharm Ltd, H2 2019
Table 29: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Incyte Corp, H2 2019
Table 30: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Karyopharm Therapeutics Inc, H2 2019
Table 31: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Lion TCR Pte Ltd, H2 2019
Table 32: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Omeros Corp, H2 2019
Table 33: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Table 34: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Oxford Vacmedix UK Ltd, H2 2019
Table 35: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Phoenicia Biosciences Inc, H2 2019
Table 36: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Sapvax LLC, H2 2019
Table 37: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Savoy Pharmaceuticals Inc, H2 2019
Table 38: Epstein-Barr Virus (HHV-4) Infections - Pipeline by TC BioPharm Ltd, H2 2019
Table 39: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Tessa Therapeutics Pte Ltd, H2 2019
Table 40: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Viracta Therapeutics Inc, H2 2019
Table 41: Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vironika LLC, H2 2019
Table 42: Epstein-Barr Virus (HHV-4) Infections - Pipeline by ViroStatics SRL, H2 2019
Table 43: Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2019
Table 44: Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 45: Epstein-Barr Virus (HHV-4) Infections - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Advenchen Laboratories LLC
  • AlloVir Inc
  • Atara Biotherapeutics Inc
  • bluebird bio Inc
  • Boryung ViGenCell Inc
  • Bristol-Myers Squibb Co
  • China Immunotech Co Ltd
  • Cullinan Oncology LLC
  • Eutilex Co Ltd
  • Galenbio Ltd
  • Geneius Biotechnology Inc
  • Genocea Biosciences Inc
  • Good T Cells Inc
  • Immunotech Biopharm Ltd
  • Incyte Corp
  • Karyopharm Therapeutics Inc
  • Lion TCR Pte Ltd
  • Omeros Corp
  • Ono Pharmaceutical Co Ltd
  • Oxford Vacmedix UK Ltd
  • Phoenicia Biosciences Inc
  • Sapvax LLC
  • Savoy Pharmaceuticals Inc
  • TC BioPharm Ltd
  • Tessa Therapeutics Pte Ltd
  • Viracta Therapeutics Inc
  • Vironika LLC
  • ViroStatics SRL
Note: Product cover images may vary from those shown
Adroll
adroll